Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Baxter
Cantor Fitzgerald
Federal Trade Commission
Citi
McKinsey
Colorcon
Johnson and Johnson
Argus Health

Generated: August 16, 2018

DrugPatentWatch Database Preview

Novartis Pharms Company Profile

« Back to Dashboard

Summary for Novartis Pharms
International Patents:1832
US Patents:115
Tradenames:54
Ingredients:44
NDAs:62

Drugs and US Patents for Novartis Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp ZYKADIA ceritinib CAPSULE;ORAL 205755-001 Apr 29, 2014 RX Yes Yes 7,153,964 ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp SIGNIFOR LAR KIT pasireotide pamoate FOR SUSPENSION;INTRAMUSCULAR 203255-002 Dec 15, 2014 RX Yes No 7,473,761 ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp PROMACTA eltrombopag olamine TABLET;ORAL 022291-001 Nov 20, 2008 RX Yes No 6,280,959*PED ➤ Sign Up Y ➤ Sign Up
Novartis Pharms Corp VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes 7,105,530 ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp JADENU SPRINKLE deferasirox GRANULE;ORAL 207968-001 May 18, 2017 RX Yes No 6,465,504 ➤ Sign Up Y Y ➤ Sign Up
Novartis Pharms Corp MEKINIST trametinib dimethyl sulfoxide TABLET;ORAL 204114-002 May 29, 2013 DISCN Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Novartis Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp ZOFRAN ondansetron hydrochloride INJECTABLE;INJECTION 020007-001 Jan 4, 1991 5,578,628*PED ➤ Sign Up
Novartis Pharms Corp TOBRADEX dexamethasone; tobramycin SUSPENSION/DROPS;OPHTHALMIC 050592-001 Aug 18, 1988 5,149,694 ➤ Sign Up
Novartis Pharms Corp ARRANON nelarabine INJECTABLE;IV (INFUSION) 021877-001 Oct 28, 2005 5,747,472 ➤ Sign Up
Novartis Pharms Corp ZOFRAN ODT ondansetron TABLET, ORALLY DISINTEGRATING;ORAL 020781-001 Jan 27, 1999 5,955,488*PED ➤ Sign Up
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 6,432,948 ➤ Sign Up
Novartis Pharms Corp XTORO finafloxacin SUSPENSION/DROPS;OTIC 206307-001 Dec 17, 2014 6,133,260 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for NOVARTIS PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Nasal Spray 0.665 mg/ Spray ➤ Subscribe 2009-06-29
➤ Subscribe Inhalation Solution 300 mg/5 mL ➤ Subscribe 2009-06-29
➤ Subscribe Otic Suspension 0.3%/0.1% ➤ Subscribe 2012-07-31
➤ Subscribe Ophthalmic Emulsion 0.05% ➤ Subscribe 2014-05-01
➤ Subscribe Tablets 180 mg ➤ Subscribe 2015-10-23
➤ Subscribe Tablets 12.5 mg and 25 mg ➤ Subscribe 2014-02-04
➤ Subscribe Tablets 250 mg ➤ Subscribe 2011-03-14
➤ Subscribe Injection 1 mg/mL, 50 mL vials ➤ Subscribe 2011-12-16
➤ Subscribe Ophthalmic Solution 0.003% ➤ Subscribe 2015-12-30
➤ Subscribe Ophthalmic Solution 0.20% ➤ Subscribe 2008-09-08
➤ Subscribe Ophthalmic Solution 0.7% ➤ Subscribe 2015-09-10
➤ Subscribe Ophthalmic 0.50% ➤ Subscribe 2005-12-22
➤ Subscribe Ophthalmic Suspension 0.3% ➤ Subscribe 2015-12-21
➤ Subscribe Tablets 2.5 mg ➤ Subscribe 2006-03-02
➤ Subscribe Tablets 90 mg and 360 mg ➤ Subscribe 2015-10-19
➤ Subscribe Tablets 50 mg and 75 mg ➤ Subscribe 2014-01-07
➤ Subscribe Tablets 180 mg ➤ Subscribe 2016-04-28
➤ Subscribe Injection 100 mg/mL, 2.5 mL vials ➤ Subscribe 2007-09-24
➤ Subscribe Oral Solution 4 mg/5 mL ➤ Subscribe 2004-12-20
➤ Subscribe Ophthalmic Solution 10.5% ➤ Subscribe 2012-02-29
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 2006-07-17
➤ Subscribe Ophthalmic Solution 0.00% ➤ Subscribe 2009-02-19

Non-Orange Book US Patents for Novartis Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,188,037 Microparticles comprising somatostatin analogues ➤ Sign Up
7,674,887 Thrombopoietin mimetics ➤ Sign Up
6,838,449 Ophthalmic compositions containing galactomannan polymers and borate ➤ Sign Up
9,499,493 2,4-pyrimidinediamine compounds and their uses ➤ Sign Up
9,399,021 Pharmaceutical composition ➤ Sign Up
7,754,733 Crystalline topotecan hydrochloride product and process for making the same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Novartis Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00068 Denmark ➤ Sign Up PRODUCT NAME: PANOBINOSTAT ELLER ET FARMACEUTISK SALT ELLER DERIVAT DERAF; REG. NO/DATE: EU/1/15/1023 20150901
C/GB12/030 United Kingdom ➤ Sign Up PRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424
2015034,C2091918 Lithuania ➤ Sign Up PRODUCT NAME: CERITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/999 20150506
0248 Netherlands ➤ Sign Up 300248, 20170624, EXPIRES: 20210827
2016000037 Germany ➤ Sign Up PRODUCT NAME: SACUBITRIL/VALSARTAN, EINSCHLIESSLICH PHARMAZEUTISCH ANNEHMBARER SALZE DAVON; REGISTRATION NO/DATE: EU/1/15/1058 20151119
C/GB12/058 United Kingdom ➤ Sign Up PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chinese Patent Office
Federal Trade Commission
Fish and Richardson
AstraZeneca
Julphar
Moodys
Citi
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.